CordenPharma Expands US Peptide Capacity
CordenPharma has expanded peptide manufacturing capacity at its GMP API facility in Boulder, Colorado, USA, to accommodate what it said is “a large spike in demand” for peptide APIs and to continue its overall growth strategy.
“With the addition of this extra-large 3,000-liter SPPS vessel, our assembly time, capacity and flexibility has been significantly increased, reinforcing CordenPharma Colorado as the current large-scale peptide manufacturing capacity leader,” said Matthieu Giraud, director of the company’s Global Peptides, Lipids & Carbohydrates Platform.
The new asset gives the company the ability to manufacture a complex long peptide with a 400 kg output per single batch, Giraud said, noting that the Colorado team aims to use the new capacity to conduct validation campaigns designed to support customer projects with a global impact.
With a 10,000-liter SPPS (Solid-Phase Peptide Synthesis) vessel and a 100-cm high-pressure reverse phase purification column, CordenPharma Colorado considers itself the largest worldwide peptide API producer and global market leader.
The purification of the final peptide can be performed at any scale in columns ranging from 5 cm to 100 cm, the CDMO said the Colorado site has a long track record in large-scale manufacturing, where all potencies, including picogram levels, can be reached.
With around 300 employees, CordenPharma has more than 130 years of cumulative experience across its global facility network in the US and Europe. This, it said, allows for a high-level of response to growing local demand at the country and community level, particularly during the ongoing COVID-19 pandemic.
